This site became the new ClinicalTrials.gov on June 19th. Learn more.
Show more
ClinicalTrials.gov Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...
ClinicalTrials.gov Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more...
ClinicalTrials.gov Menu
Give us feedback

Migraine Prevention Using ActiPatch (PSWT)

This study is currently recruiting participants.
See Contacts and Locations
Verified May 2017 by BioElectronics Corporation
Sponsor:
Information provided by (Responsible Party):
BioElectronics Corporation
ClinicalTrials.gov Identifier:
NCT03166046
First received: May 22, 2017
Last updated: May 23, 2017
Last verified: May 2017
May 22, 2017
May 23, 2017
June 1, 2017
November 21, 2017   (Final data collection date for primary outcome measure)
  • Migraine frequency [ Time Frame: 4 weeks ]
    frequency of migraine attacks
  • Migraine duration [ Time Frame: 4 weeks ]
    Duration of migraine attacks
Same as current
No Changes Posted
  • Migraine intensity measured with Visual Analogue Pain Score [ Time Frame: 4 weeks ]
    Migraine intensity measured with visual analogue pain score (VAS scores)
  • Headache disability measured with Headache Impact Test [ Time Frame: 4 weeks ]
    Headache impact test (HIT-6)
Same as current
Not Provided
Not Provided
 
Migraine Prevention Using ActiPatch
Migraine Prevention Using Pulsed Shortwave Therapy
Chronic pain is now widely understood to be due to central sensitization, which leads to exaggerated pain perception. Migraine is no exception, since it is well known that sensitization of the trigeminovascular pain pathway can occur during a migraine attach. There is early evidence that ActiPatch can help mitigate this sensitization, so this study is being conducted to determine the efficacy of ActiPatch in preventing chronic, episodic migraines.

Migraine is a common neurological disorder characterized by episodes of unilateral or bilateral headache lasting for hours to days, which may be accompanied by photophobia, phonophobia, nausea and vomiting. Pharmacological management is the first treatment option for subjects with migraine. However, some patients do not tolerate acute and/or prophylactic medicine due to side effects or contraindications due to comorbidity of other diseases or due to a wish to avoid medication for other reasons. The risk of medication overuse due to frequent migraine attacks represents a major health hazard with direct and indirect cost concerns. The prevalence of medication overuse headache is 1 -2% in the general population, that is, about half the population suffering chronic headache (15 headache days or more per month) have medication overuse headache.It is well-known that a primary brain dysfunction leads to episodic activation and sensitization of the trigeminovascular pain pathway during attacks. However, a functional and anatomic relationship exists between peripheral afferent nerves supplying the head and neck and the brainstem, subcortical and higher order brain processing centers. There is some evidence that interventions targeting peripheral nerves are able to modulate neuronal circuits involved in pain control and that they could be useful in some selected patients with migraine.

Supraorbital neurostimulation (tSNS) of the upper branches of the trigeminal nerves was found superior to sham stimulation for episodic migraine prevention in a previous randomized trial in a large cohort of patients with migraine. In this study the pulsed shortwave device will be incorporated in a wrap which will enable easy placement of the device in the desired located which will be over the supratrochlear and supraorbital branches of the ophthalmic nerve.

Interventional
Phase 1
Allocation: Randomized
Intervention Model: Parallel Assignment
Intervention Model Description:
Randomized, double blind, placebo controlled trial using an active pulsed shortwave therapy device or placebo pulsed shortwave therapy device
Masking: Participant, Care Provider, Investigator, Outcomes Assessor
Masking Description:
Coded devices that are identical in appearance and function. Placebo device does not emit electromagnetic field. Active device electromagnetic field is sub-sensory.
Primary Purpose: Treatment
Migraine
  • Device: Pulsed Shortwave Therapy
    Stimulation of the supratrochlear and supraorbital branches of the ophthalmic nerve.
    Other Name: ActiPatch
  • Device: Placebo Pulsed Shortwave therapy
    Placebo Stimulation of the supratrochlear and supraorbital branches of the ophthalmic nerve.
    Other Name: Placebo ActiPatch
  • Active Comparator: Study Group
    Subjects will use the active pulsed shortwave therapy device (ActiPatch) as a prophylactic treatment for episodic migraine
    Intervention: Device: Pulsed Shortwave Therapy
  • Placebo Comparator: Control Group
    Subjects will use the placebo pulsed shortwave therapy device (Placebo ActiPatch) as a prophylactic treatment for episodic migraine
    Intervention: Device: Placebo Pulsed Shortwave therapy
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Recruiting
80
December 30, 2017
November 21, 2017   (Final data collection date for primary outcome measure)

Inclusion Criteria:

  • Participant is willing and able to give informed consent for participation in the trial.
  • In the Investigator's opinion, is able and willing to comply with all trial requirements.
  • Male or female ages 18 or above with migraine headache
  • 3 or greater occurrences of migraine per month
  • no prior use of neuromodulation for migraine headache

Exclusion Criteria:

  • Female participant who is pregnant
  • prior use of neuromodulation for migraine headache
  • Laminectomy, laminotomy or discectomy within 12 months of enrollment.
  • Active psychiatric disorders will be excluded (e.g. use of antipsychotic medication, bipolar disorder, schizophrenia).
  • Patients diagnosed with history of significant mood disorder will be excluded (e.g., depression or anxiety with adequate control would be acceptable).
  • Scheduled elective surgery or other procedures requiring general anaesthesia during the trial.
  • Any other significant disease or disorder which, in the opinion of the Investigator, may either put the participants at risk because of participation in the trial, or may influence the result of the trial, or the participant's ability to participate in the trial.
  • Participants who have participated in another research trial involving an investigational product in the past 12 weeks.
Sexes Eligible for Study: All
18 Years to 80 Years   (Adult, Senior)
No
Contact: Barry L Eppley, MD, DMD 317-706-4444 beppley@eppleyplasticsurgery.com
Contact: Sree Koneru, Ph.D 301-874-4890 skoneru@bielcorp.com
United States
 
 
NCT03166046
SAIRB-17-0021
No
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: Yes
Device Product Not Approved or Cleared by U.S. FDA: No
Product Manufactured in and Exported from the U.S.: No
Plan to Share IPD: No
BioElectronics Corporation
BioElectronics Corporation
Not Provided
Not Provided
BioElectronics Corporation
May 2017

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP